IRON

Business Context and Reporting Period

Company: Disc Medicine, Inc. (Nasdaq: IRON)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2026
Business Overview: Disc Medicine is a clinical-stage biopharmaceutical company focused on novel treatments for serious hematologic diseases. Its pipeline includes bitopertin (erythropoietic porphyrias), selcodebart (anemia of myelofibrosis and IBD), and DISC-3405 (polycythemia vera and sickle cell disease). The company has no approved products and has not generated product revenue.

Key Financial Metrics

Material Changes vs. Prior Period

• Net Loss Increase: Net loss for the six months ended June 30, 2026, increased by $33.7 million (37.7%) compared to the same period in 2025, driven primarily by higher operating expenses.
• R&D Expenses: R&D expenses increased by $18.8 million year-over-year for the six-month period. This was driven by increased clinical and manufacturing activities for selcodebart and DISC-3405, and a $5.0 million milestone payment for DISC-3405. These increases were partially offset by a $14.1 million decrease in bitopertin expenses due to the absence of a $10.0 million milestone payment incurred in the prior year.
• SG&A Expenses: SG&A expenses increased by $14.5 million year-over-year, primarily due to increased personnel-related costs (including stock-based compensation) and organizational restructuring costs.
• Debt Position: Long-term debt increased significantly from $29.2 million to $59.3 million. In June 2026, the company drew an additional $30.0 million tranche under its Hercules Loan Agreement, bringing the total principal balance to $60.0 million.
• Investing Activities: Net cash provided by investing activities was $79.9 million for the six months ended June 30, 2026, compared to net cash used of $220.9 million in the prior year period, due to maturities of marketable securities exceeding purchases.

Guidance, Outlook, and Risks

• Liquidity Outlook: Management expects existing cash, cash equivalents, and marketable securities ($717.7 million) to fund operations and debt service obligations into 2029.
• Bitopertin Regulatory Status: The FDA issued a Complete Response Letter (CRL) in February 2026 regarding the NDA for accelerated approval of bitopertin. The FDA concluded that Phase 2 data did not demonstrate an association between the biomarker (PPIX) and clinical benefit (sunlight exposure). The company plans to submit a response to the CRL based on topline data from the ongoing Phase 3 APOLLO trial, expected in Q4 2026, with a potential FDA decision by mid-2027.
• Clinical Milestones:
  • Selcodebart: Interim data from the RALLY-MF Phase 2 trial was reported in June 2026. An end-of-Phase 2 meeting with the FDA is expected by the end of 2026.
  • DISC-3405: Initial data from the RESTORE-PV Phase 2 trial is expected in Q3 2026, and Phase 1b data for sickle cell disease is expected in Q4 2026.
• Key Risks:
  • Regulatory Uncertainty: Failure of the APOLLO trial could prevent approval of bitopertin.
  • Capital Requirements: The company anticipates continued losses and may need to raise additional capital if development timelines extend or if approval is delayed.
  • Debt Covenants: The Hercules Loan Agreement includes a minimum cash covenant effective July 1, 2028 (or 2029 if a milestone is met), which could restrict operations if not met.

Investor Verification Checklist

• APOLLO Trial Data: Verify the timing and results of the Phase 3 APOLLO trial topline data (expected Q4 2026) as this is critical for bitopertin approval.
• Debt Covenants: Review the specific terms of the minimum cash covenant in the Hercules Loan Agreement and the company's projected cash runway relative to the 2028/2029 trigger dates.
• Burn Rate: Monitor the quarterly cash burn rate, particularly given the increase in R&D and SG&A expenses, to assess the validity of the "into 2029" liquidity guidance.
• Milestone Payments: Track upcoming clinical milestones for selcodebart and DISC-3405 that could trigger significant cash outflows under licensing agreements with AbbVie and Mabwell.
• Stock-Based Compensation: Note the significant increase in stock-based compensation ($25.9 million for the six months ended June 30, 2026) and its impact on future dilution and expense management.